Daily Chart

Merck & Co. Inc. (MRK) Financial News - Novartis has no need to buy Intercell-source

Merck & Co. Inc. (MRK)

Novartis has no need to buy Intercell-source

Keywords: Ben Hirschler
Quote: The rationale for the strategic partnership with Intercell was to gain access to innovation in vaccines, and that has not changed," Andrin Oswald, head of Novartis' Vaccines and Diagnostics unit, said. Last month, Intercell's partner Merck & Co (MRK.N) decided to discontinue a major trial of a vaccine designed to protect against serious hospital infections, adding to worries about Intercell's pipeline's prospects. [ID:nLDE757026] The group's stock has lost over 74 percent of its value so far this year as various disappointments have weighed on its volatile shares. Intercell has a free float of nearly 82 percent and is worth around $206 million. Lingelbach has said he still sees further growth of Intercell's only marketed product, Ixiaro, a vaccine for Japanese encephalitis, which is a mosquito-borne virus that causes inflammation of the brain. Intercell is hoping for 60 to 70 percent sales growth this year for the vaccine, though the product's prospects took a knock earlier this year when Intercell had to recall batches in Europe due to a possible loss of potency. Intercell distributes the vaccine with Novartis. [ID:nLDE74Q0GR](Editing by Ben Hirschler) ...
Open whole article (external link)

Other Financial and Stock Market News concerning Merck & Co. Inc.

Merck & Co. Inc. Stock Summary

Stocktweeting is not a financial advisor, and in no way recommends the purchase of any stock or advise on the suitability of any trade or investment.
Stock trading and investing can cause loss of capital, and you should always consult with a professional financial advisor before trading or investing.

This website is a service of the HagensMedia ad network. For advertising please visit http://www.hagensmedia.com - Copyright 2015.